Isolation and identification of urinary metabolites of porfiromycin in dogs and humans

Drug Metabolism and Disposition

Volumn 28, Issue 8, 2000, Pages 899-904

  Lang, W ^a   Mao, J ^a   Doyle, T W ^a   Almassian, B ^a  

^a Vion Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PORFIROMYCIN;

ARTICLE; DRUG DISPOSITION; DRUG FECES LEVEL; DRUG ISOLATION; DRUG URINE LEVEL; GLUTATHIONE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID SCINTILLATION COUNTING; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; PORFIROMYCIN; RADIOPHARMACEUTICALS; TRITIUM;

CANIS FAMILIARIS;

EID: 0033863119     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Phase II study of porfiromycin vs. mitomycin C utilizing acute intermittent schedules
2. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases
3. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase
4. Renal processing of glutathione conjugates
5. Phase I studies of porfiromycin (NSC-56410)
6. Cytotoxicity and DNA lesions produced by mitomycin and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells
7. Phase I studies of porfiromycin (NSC-56410) in solid tumors
8. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors
9. Reductive activation of mitomycin by NADH:cytochrome b5 reductase
10. 2 for the reductive activation of mitomycin C
11. Biological active intermediates generated by the reduced glutathione conjugation pathway
12. Mitomycin and porfiromycin: Chemical mechanism of activation and cross-linking of DNA
13. Further clinical trials with porfiromycin (NSC-56410) (large intermittent doses)
14. Metabolic activation of mitomycin C by liver microsomes and nuclei
15. The role of glutathione in detoxication
16. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C
17. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro
18. Isolation and identification of metabolites of porfiromycin formed in the presence of a rat liver preparation
19. Phase I trial of porfiromycin (NSC-56410)
20. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells
21. Bioactivation as a model for drag design bioreductive alkylation
22. Porfiromycin disposition in oxygen-modulated P388 cells
23. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells
24. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P450 reductase and xanthine oxidase
25. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells
26. Metabolites and DNA-adduct formation from flavoenzyme-activated porfiromycin
27. DNA-alkylation by enzyme-activated mitomycin C
28. The sensitivity of human tumor cells to quinone bioreductive drugs: What role for DT-diaphorase?
29. Porfiromycin as an adjunct to radiotherapy in young and old mice
30. Preclinical studies of porfiromycin as an adjunct to radiotherapy
31. Pharmacology of mitomycin C: III. In vitro metabolism by rat liver
32. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C- induced DNA damage and cytotoxicity in human colon carcinoma cells
33. Reductive metabolism and alkylating activity of mitomycin C induced by rat liver microsomes